Patents by Inventor Scott Richard Daigle

Scott Richard Daigle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230201212
    Abstract: The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations, or exhibits a genetic profile, listed in Tables 1-5, and/or FIGS. 1-3.
    Type: Application
    Filed: June 13, 2018
    Publication date: June 29, 2023
    Inventors: Stephen BLAKEMORE, Scott Richard DAIGLE
  • Patent number: 11633420
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: April 25, 2023
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • Publication number: 20220193084
    Abstract: The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. 19-22.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Inventors: Stephen BLAKEMORE, Scott Richard DAIGLE
  • Publication number: 20210268012
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: January 4, 2021
    Publication date: September 2, 2021
    Inventors: Edward J. OLHAVA, Richard CHESWORTH, Kevin W. KUNTZ, Victoria M. RICHON, Roy M. POLLOCK, Scott Richard DAIGLE
  • Publication number: 20210052595
    Abstract: The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. 19-22.
    Type: Application
    Filed: December 7, 2016
    Publication date: February 25, 2021
    Inventors: Stephen BLAKEMORE, Scott Richard DAIGLE
  • Patent number: 10881680
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: January 5, 2021
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • Publication number: 20200030355
    Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: January 16, 2019
    Publication date: January 30, 2020
    Inventors: Christine KLAUS, Maria Alejandra RAIMONDI, Scott Richard DAIGLE, Roy MacFarlane POLLOCK, Vivek CHOPRA
  • Publication number: 20190216838
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 10, 2018
    Publication date: July 18, 2019
    Inventors: Edward J. OLHAVA, Richard CHESWORTH, Kevin W. KUNTZ, Victoria M. RICHON, Roy M. POLLOCK, Scott Richard DAIGLE
  • Publication number: 20190083521
    Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 12, 2015
    Publication date: March 21, 2019
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock
  • Publication number: 20180028552
    Abstract: The present disclosure relates to a combination of an inhibitor of human histone methyltransferase DOT1L, such as EPZ-5676 or salts thereof, and one or more DNMT inhibitors, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: February 1, 2016
    Publication date: February 1, 2018
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock, Vivek Chopra
  • Publication number: 20170232030
    Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 12, 2015
    Publication date: August 17, 2017
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock, Vivek Chopra
  • Publication number: 20170165288
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 15, 2017
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • Patent number: 9597348
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: March 21, 2017
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • Publication number: 20160045531
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock
  • Publication number: 20150216890
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: September 6, 2013
    Publication date: August 6, 2015
    Applicant: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • Patent number: 8580762
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: November 12, 2013
    Assignee: Epizyme, Inc.
    Inventors: Edward James Olhava, Richard Chesworth, Kevin Wayne Kuntz, Victoria M. Richon, Roy Macfarlane Pollock, Scott Richard Daigle